1 Ocak 2023 Dergi makalesi Açık Erişim

Senol, Halil; Ozgun-Acar, Ozden; Dag, Aydan; Eken, Ahmet; Guner, Huseyin; Aykut, Zaliha Gamze; Topcu, Gulacti; Sen, Alaattin

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 273276, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Bezmialem Vakif Univ, Fac Pharm, Dept Pharmaceut Chem, TR-34093 Istanbul, Turkiye", 
      "name": "Senol, Halil"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Pamukkale Univ, Seed Breeding & Genet Applicat Res Ctr, TR-20070 Denizli, Turkiye", 
      "name": "Ozgun-Acar, Ozden"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Bezmialem Vakif Univ, Fac Pharm, Dept Pharmaceut Chem, TR-34093 Istanbul, Turkiye", 
      "name": "Dag, Aydan"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Med Biol Erciyes Univ, Fac Med, Dept Basic Med Sci, TR-38039 Kayseri, Turkiye", 
      "name": "Eken, Ahmet"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Univ Abdullah Gul, Fac Life & Nat Sci, Dept Mol Biol & Genet, TR-38080 Kayseri, Turkiye", 
      "name": "Guner, Huseyin"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Bilkent Univ, Lab Anim Facil, TR-06800 Ankara, Turkiye", 
      "name": "Aykut, Zaliha Gamze"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Bezmialem Vakif Univ, Fac Pharm, Dept Pharmacognosy & Phytochemistry, TR-34093 Istanbul, Turkiye", 
      "name": "Topcu, Gulacti"
    }, 
    {
      "@type": "Person", 
      "name": "Sen, Alaattin"
    }
  ], 
  "datePublished": "2023-01-01", 
  "description": "<p>Multiple sclerosis (MS) treatment has received much attention, yet there is still no certain cure. We herein investigate the therapeutic effect of olean-12-en-28-ol, 3 beta- pentacosanoate (OPCA) on a preclinical model of MS. First, OPCA was synthesized semisynthetically and characterized. Then, the mice with MOG35-55-induced experimental autoimmune/ allergic encephalomyelitis (EAE) were given OPCA along with a reference drug (FTY720). Biochemical, cellular, and molecular analyses were performed in serum and brain tissues to measure anti-inflammatory and neuroprotective responses. OPCA treat-ment protected EAE-induced changes in mouse brains maintaining blood-brain barrier integrity and preventing inflammation. Moreover, the protein and mRNA levels of MS-related genes such as HLD-DR1, CCL5, TNF-alpha, IL6, and TGFB1 were significantly reduced in OPCA-treated mouse brains. Notably, the expression of genes, including PLP, MBP, and MAG, involved in the development and structure of myelin was significantly elevated in OPCA-treated EAE. Furthermore, therapeutic OPCA effects included a substantial reduction in pro-inflammatory cytokines in the serum of treated EAE animals. Lastly, following OPCA treatment, the promoter regions for most inflammatory regulators were hypermethylated. These data support that OPCA is a valuable and appealing candidate for human MS treatment since OPCA not only normalizes the pro-and anti-inflammatory immunological bias but also stimulates remyelination in EAE.</p>", 
  "headline": "Synthesis and Comprehensive in Vivo Activity Profiling of Olean-12-en-28-ol, 3\u03b2-Pentacosanoate in Experimental Autoimmune Encephalomyelitis: A Natural Remyelinating and Anti-Inflammatory Agent", 
  "identifier": 273276, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Synthesis and Comprehensive in Vivo Activity Profiling of Olean-12-en-28-ol, 3\u03b2-Pentacosanoate in Experimental Autoimmune Encephalomyelitis: A Natural Remyelinating and Anti-Inflammatory Agent", 
  "url": "https://aperta.ulakbim.gov.tr/record/273276"
}